HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Neugroschl, J. Articles by Davis, K. L. Search for Related Content PubMed PubMed Citation Articles by Neugroschl, J. Articles by Davis, K. L.

Biological Markers in Alzheimer Disease

Received March 28, 2002; revised and accepted August 9, 2002. From the Department of Psychiatry, Mount Sinai School of Medicine, New York, NY. Address correspondence to Dr. Davis, Box 1230, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029.

Biological markers are important tools in identifying predisposing factors to disease, as diagnostic tests, and in monitoring disease progression. Alzheimer disease is believed to have a long preclinical phase, followed by mild cognitive impairment, and, finally, dementia. Detecting alterable predisposing factors or identifying patients in preclinical or early-stage illness offers the greatest potential to modifying disease course. The authors focus on: 1) predisposing factors, such as genetic risk factors and homocysteine; 2) laboratory markers, such as amyloid beta and tau protein; and 3) diagnostic markers, such as structural and functional neuroimaging. Many markers have been tested but have not been confirmed in subsequent studies. Other tests require complex and expensive laboratory evaluation or expertise, thereby limiting their use at present. Still others are markers only useful in later-stage illness. Nonetheless, the search for markers has increased our understanding of the biology of illness and has led to exciting new directions, with diagnostic as well as treatment implications.

Key Words: Alzheimer's Disease • Neuroimaging • PET • SPECT • fMRI

This article has been cited by other articles:

				I. I. Gottesman and T. D. Gould The Endophenotype Concept in Psychiatry: Etymology and Strategic Intentions Am J Psychiatry, April 1, 2003; 160(4): 636 - 645. [Abstract] [Full Text] [PDF]

				B. G. Pollock Biomarkers: From Bedside to Bench and Back Again Am J Geriatr Psychiatry, December 1, 2002; 10(6): 644 - 645. [Full Text] [PDF]